The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

In one aspect, the invention relates to compounds having the formula XII: ##STR00001##
where R.sup.a, R.sup.b, R.sup.2, R.sup.7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

In one aspect, the invention relates to compounds having the formula XII: ##STR00001##
where R.sup.a, R.sup.b, R.sup.2, R.sup.7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Disclosed is a compound of formula (I):

##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Disclosed is a compound of formula (I):

##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

The present invention provides a hydraulic fluid comprising: (a) 40 to 2000 ppm by weight in terms of nitrogen content of a corrosion inhibiting agent which is one or more compounds of formula (I): ##STR00001## and/or tribologically acceptable salts thereof, wherein in formula (I): each R.sup.1 is independently a hydrocarbyl group comprising 1 to 10 carbon atoms, x is 0 to 4, each of R.sup.2 and R.sup.3 is independently hydrogen or a hydrocarbyl group comprising 1 to 20 carbon atoms, R.sup.4 is —NR.sup.5R.sup.6 or —OR.sup.7, each of R.sup.5 and R.sup.6 is independently an aryl group comprising 6 to 14 carbon atoms, optionally substituted with one or more hydrocarbyl groups comprising 1 to 20 carbon atoms, R.sup.7 is a hydrocarbyl group comprising 1 to 20 carbon atoms, and in each of said hydrocarbyl groups containing 2 or more carbon atoms, the carbon chain may, independently, optionally be interrupted by one or more ether groups; (b) 0.1 to 1% by weight of an ashless dispersant; and (c) a major amount of a base oil.

The present invention provides a hydraulic fluid comprising: (a) 40 to 2000 ppm by weight in terms of nitrogen content of a corrosion inhibiting agent which is one or more compounds of formula (I): ##STR00001## and/or tribologically acceptable salts thereof, wherein in formula (I): each R.sup.1 is independently a hydrocarbyl group comprising 1 to 10 carbon atoms, x is 0 to 4, each of R.sup.2 and R.sup.3 is independently hydrogen or a hydrocarbyl group comprising 1 to 20 carbon atoms, R.sup.4 is —NR.sup.5R.sup.6 or —OR.sup.7, each of R.sup.5 and R.sup.6 is independently an aryl group comprising 6 to 14 carbon atoms, optionally substituted with one or more hydrocarbyl groups comprising 1 to 20 carbon atoms, R.sup.7 is a hydrocarbyl group comprising 1 to 20 carbon atoms, and in each of said hydrocarbyl groups containing 2 or more carbon atoms, the carbon chain may, independently, optionally be interrupted by one or more ether groups; (b) 0.1 to 1% by weight of an ashless dispersant; and (c) a major amount of a base oil.

Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.